Clinical trial · no report yet · Phase 2
DESTINY-CRC02
Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer
- NCT04744831 ↗
- Completed
- Daiichi Sankyo
- 90 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 31 | |
| YouTube | 30 | |
| Podcasts | 29 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2, Multicenter, Randomized, Study of Trastuzumab Deruxtecan in Participants With HER2-overexpressing Locally Advanced, Unresectable or Metastatic Colorectal Cancer (DESTINY-CRC02)
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Advanced Colorectal Cancer
- Interventions
- DS-8201a 5.4 mg/kg Q3W; DS-8201a 6.4 mg/kg Q3W
- Arms
- T-DXd 5.4 mg/kg Q3W · Experimental
- T-DXd 6.4 mg/kg Q3W · Experimental
- Enrollment
- 122
- Primary outcomes
- Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review Following IV Administration of T-DXd in Participants With Human Epidermal Growth Factor Receptor 2-overexpressing Metastatic Colorectal Cancer
- Sponsor
- Daiichi Sankyo with AstraZeneca
- Start
- Mar 5, 2021
- Primary completion
- Nov 1, 2022
- Results posted
- Yes
- Registry record
- NCT04744831 · updated Jan 14, 2026
Publications
linked from the registry- Raghav K. Trastuzumab deruxtecan in HER2-positive advanced colorectal cancer: a plain language summary of the DESTINY-CRC02 study. Future Oncol. 2026 Jan;22(2):123-135. doi: 10.1080/14796694.2025.2606418. Epub 2026 Jan 5. PubMed 41487064
- Raghav K, Siena S, Takashima A, Kato T, Van den Eynde M, Pietrantonio F, Komatsu Y, Kawakami H, Peeters M, Andre T, Lonardi S, Yamaguchi K, Tie J, Castro CG, Hsu HC, Strickler JH, Kim TY, Cha Y, Barrios D, Yan Q, Kamio T, Kobayashi K, Boran A, Koga M, Allard JD, Yoshino T. Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial. Lancet Oncol. 2024 Sep;25(9):1147-1162. doi: 10.1016/S1470-2045(24)00380-2. Epub 2024 Aug 5. PubMed 39116902